1 Answers
Lucentis Intravitreal Injection contains Ranibizumab
Lucentis Intravitreal Injection uses for
Ranibizumab is indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (Non Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR)) in patients with Diabetic Macular Edema (DME)
- Myopic Choroidal Neovascularization (mCNV)
Intravitreal (Adult)-
Neovascular (wet) age-related macular degeneration: 0.5 mg mthly into the affected eye as a single dose. Continue treatment until visual acuity is stable for 3 consecutive mth. Doses are given at intervals of at least 1 mth.
Choroidal neovascularisation secondary to pathologic myopia: 0.5 mg into the affected eye as a single dose. Further injections may be given if monitoring reveals signs of disease activity (1 inj during the 1st yr; some patients may need more frequent treatment). Doses are given at intervals of at least 1 mth.
Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion: 0.5 mg mthly into the affected eye as a single dose. Continue treatment until visual acuity is stable for 3 consecutive mth. Doses are given at intervals of at least 1 mth. Discontinue treatment if no improvement in visual acuity after 3 initial inj.
Symptoms: Increased intraocular pressure, transient blindness, reduced visual acuity, corneal oedema, corneal pain, and eye pain.
Management: Intraocular pressure should be monitored and treated by the attending physician, if necessary.
Read more here Lucentis